Phase 1 dose‐escalation study of single‐agent veliparib in Japanese patients with advanced solid tumors

Veliparib (ABT‐888) is a potent, orally bioavailable poly(ADP‐ribose) polymerase‐1 and ‐2 inhibitor. This phase 1 study evaluated the tolerability, pharmacokinetic profile, safety, and preliminary antitumor activity of single‐agent veliparib in Japanese patients with advanced solid tumors. Eligible...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishikawa, Tadaaki, Matsumoto, Koji, Tamura, Kenji, Yoshida, Hiroyuki, Imai, Yuichi, Miyasaka, Aki, Onoe, Takuma, Yamaguchi, Satoshi, Shimizu, Chikako, Yonemori, Kan, Shimoi, Tatsunori, Yunokawa, Mayu, Xiong, Hao, Nuthalapati, Silpa, Hashiba, Hideyuki, Kiriyama, Tsukasa, Leahy, Terri, Komarnitsky, Philip, Fujiwara, Keiichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581522/
https://www.ncbi.nlm.nih.gov/pubmed/28665051
http://dx.doi.org/10.1111/cas.13307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581522/
https://www.ncbi.nlm.nih.gov/pubmed/28665051
http://dx.doi.org/10.1111/cas.13307

Ejemplares similares